ProMIS Reports First Human PMN310 Evidence
CAMBRIDGE, Mass., July 14, 2026 ProMIS Neurosciences presented the first human evidence that its investigational Alzheimer’s disease therapy PMN310...
Phase 1b
Advertisement
Kura Oncology Presents Darlifarnib Plus Cabozantinib Data
SAN DIEGO, July 14, 2026 Kura Oncology announced that updated long-term follow-up data from the ongoing FIT-001 Phase 1a...
Agenus Reports Three-Year BOT+BAL Survival Data
LEXINGTON, Mass., July 6, 2026 Agenus announced new three-year follow-up results from the fully enrolled Phase 1b C-800-01 study...
Kenai Therapeutics Completes Phase 1b/2a REPLACE Trial Enrollment
SAN DIEGO, July 7, 2026 Kenai Therapeutics has announced the successful completion of patient enrollment in the Phase 1b/2a...
AnaCardio Publishes AC01 Heart Failure Study in The Lancet
STOCKHOLM, Sweden, June 25, 2026 AnaCardio announced that results from its Phase 1b/2a GOAL-HF1 clinical trial evaluating AC01, a...
Advertisements
Cambrian Bio Reports Positive Phase 1b ATX-304 Data
NEW YORK, N.Y. | June 18, 2026 Cambrian Bio has presented positive Phase 1b clinical data for ATX-304, the...
TuHURA Files IND for TBS-2025 in AML and Blood Cancers
TAMPA, Fla., June 15, 2026 TuHURA Biosciences, Inc. has announced the filing of an Investigational New Drug (IND) application...
Tenaya Gene Therapy Shows Strong Arrhythmia Reduction in ARVC Trial
SOUTH SAN FRANCISCO, Calif., May 15, 2026 Tenaya Therapeutics reported encouraging interim Phase 1b/2 clinical data for TN-401, its...
Kodiak KSI-101 Shows Strong MESI Clinical Trial Results
Palo Alto, California, United States | May 1, 2026 Kodiak Sciences Inc. has announced new clinical and pipeline advancements...
KSI-101 Phase 1b Data Advance Inflammatory Macular Therapy
PALO ALTO, Calif., Feb. 4, 2026 —Kodiak Sciences Inc. announced that final end-of-study Phase 1b APEX clinical results evaluating...
Advertisement
